Subcutaneous Biodegradable Reservoir Membrane for Flat Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current long-acting drug delivery systems for HIV PrEP and other therapeutics face challenges such as non-zero-order drug release kinetics, potential adverse events, and difficulty in removing the device in case of adverse drug reactions, leading to sub-therapeutic drug levels and adherence issues.
Innovation Solution
A biodegradable, permeable polymer membrane reservoir device with a thickness of at least 45 μm for subcutaneous use, allowing zero-order release kinetics of active agents like Tenofovir alafenamide fumarate (TAF) and 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) for sustained delivery over 60 days, with tunable release profiles and biodegradation after agent depletion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If a non-biodegradable reservoir device is used for sustained drug delivery, then the duration of action is extended, but the device cannot be removed in case of adverse drug reactions
Solution Approach 1:
The patent applies parameter changes by transitioning from non-biodegradable to biodegradable polymer materials. The biodegradable polymer membrane undergoes controlled degradation over time, changing its physical properties from intact to fragmented, enabling automatic device dissolution and elimination after drug depletion, thus resolving the contradiction between extended duration and ease of removal.
Solution Approach 2:
The patent converts the potential harm of device retention (adverse events) into a benefit by designing biodegradable polymers that automatically degrade and eliminate. The degradation process, which could be seen as a loss of structural integrity, is actually the desired outcome for safe device elimination, transforming the problem of device removal into an automatic self-elimination mechanism.
2Duration of action of moving object
If the polymer membrane thickness is increased to sustain drug delivery over 60 days, then the duration of action is extended, but the diffusion rate of active agent may be reduced
Solution Approach 1:
The patent applies parameter changes by systematically optimizing multiple parameters including polymer membrane thickness (at least 45 μm), crosslinking density, polymer composition, and drug formulation. These parameter adjustments enable the membrane to maintain both sufficient thickness for 60-day duration and adequate porosity for consistent zero-order release kinetics.
Solution Approach 2:
The patent employs composite materials by combining biodegradable polymers with specific crosslinking agents and drug formulations. The composite structure of crosslinked polymer networks with controlled porosity allows simultaneous achievement of mechanical strength (for thickness), degradation control (for duration), and drug diffusion (for release consistency).
3Stability of the object's composition
If zero-order release kinetics is achieved through membrane control, then the plasma concentration profile becomes flat and consistent, but the device complexity increases
Solution Approach 1:
The patent achieves zero-order release kinetics by carefully controlling membrane parameters including thickness, crosslinking density, and polymer composition. By optimizing these parameters, the membrane provides rate-controlled drug release that maintains flat plasma concentration profiles without requiring complex multi-component systems or active control mechanisms.
Solution Approach 2:
The patent replaces complex mechanical control systems with a passive diffusion-based mechanism. Instead of using pumps, valves, or active release mechanisms, the invention relies on Fickian diffusion through the biodegradable polymer membrane, where the concentration gradient and membrane properties alone control the zero-order release kinetics, significantly simplifying the device structure.
4Duration of action of moving object
If a biodegradable polymer membrane with thickness of at least 45 μm is used, then the device provides sustained delivery over 60 days, but the manufacturing precision requirements increase
Solution Approach 1:
The patent establishes a minimum thickness parameter (at least 45 μm) that provides a manufacturing buffer. This parameter setting allows reasonable variation during manufacturing while ensuring all devices meet the 60-day duration requirement. The specification provides clear guidance for quality control without requiring ultra-precise thickness control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device provides a flat plasma concentration profile and minimizes the drug tail, ensuring consistent therapeutic levels and ease of removal upon depletion, addressing adherence issues and safety concerns.
Implementation Method 1
The membrane allows for diffusion of an active agent of the formulation there through when positioned subcutaneously in a body of a subject
Implementation Method 2
A biodegradable, permeable polymer membrane reservoir device
Data Source
AI summary
A reservoir device comprising an active agent formulation contained within a reservoir is described. The reservoir is defined by a biodegradable, permeable polymer membrane having a thickness of at least 45 μm. The membrane allows for diffusion of an active agent of the formulation there through when positioned subcutaneously in a body of a subject.